Financing drug discovery for orphan diseases
Recently proposed 'megafund' financing methods for funding translational medicine and drug development require billions of dollars in capital per megafund to de-risk the drug discovery process enough to issue long-term bonds. Here, we demonstrate that the same financing methods can be appl...
Main Authors: | Gromatzky, Austin A. (Contributor), Stein, Roger Mark (Contributor), Fernandez, Jose-Maria (Contributor), Fagnan, David E. (Author), Lo, Andrew W (Author) |
---|---|
Other Authors: | Massachusetts Institute of Technology. Computer Science and Artificial Intelligence Laboratory (Contributor), Massachusetts Institute of Technology. Department of Biology (Contributor), Massachusetts Institute of Technology. Operations Research Center (Contributor), Sloan School of Management (Contributor), Sloan School of Management. Laboratory for Financial Engineering (Contributor), Fagnan, David Erik (Contributor), Lo, Andrew W. (Contributor) |
Format: | Article |
Language: | English |
Published: |
Elsevier B.V.,
2014-10-09T16:58:33Z.
|
Subjects: | |
Online Access: | Get fulltext |
Similar Items
-
Analytics for financing drug development
by: Fagnan, David Erik
Published: (2015) -
Financing rare or orphan diseases
by: Alfredo Oyola-García, et al.
Published: (2014-12-01) -
Financing drug discovery via dynamic leverage
by: Frishkopf, John J., et al.
Published: (2017) -
Availability of Orphan drugs: Basic legal issues of development and financing
by: Stojković-Zlatanović Sanja
Published: (2019-01-01) -
Financing translation: Analysis of the NCATS rare-diseases portfolio
by: Fagnan, David E., et al.
Published: (2015)